Nature (10/19/89) Vol. 341, No. 6243, P. 566
The lack of standard reagents, including viruses, makes comparing AIDS
research from different laboratories problematic, especially in the case
of vaccine research. In Europe, the European Communities have launched
the EVA, or European vaccine against AIDS, which will use most of its 2.5
million ECU budget for production and distribution of reagents. The
National Institute for Biological Standards and Control in South Mimms,
United Kingdom, will monitor quality control, storage, and distribution
of the reagents, which will be produced in several laboratories to agreed
specifications.